A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

ClinicalTrials.gov ID: NCT06500702

Public ClinicalTrials.gov record NCT06500702. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 6, 2026, 8:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Parallel-group Treatment, Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Umbrella Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, and Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

Study identification

NCT ID: NCT06500702
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Sanofi; Industry
Enrollment: 84 participants

Conditions and interventions

Conditions

Interventions

brivekimig Drug
frexalimab Drug
placebo Drug
rilzabrutinib Drug

Drug

Eligibility (public fields only)

Age range: 16 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 18, 2024
Primary completion: Dec 22, 2026
Completion: Feb 15, 2028
Last update posted: May 4, 2026

2024 – 2028

United States locations

U.S. sites: 15
U.S. states: 11
U.S. cities: 15

Facility	City	State	ZIP	Site status
Investigational Site Number : 8400007	Birmingham	Alabama	35233	Recruiting
Investigational Site Number : 8400015	Orange	California	92868	Recruiting
Investigational Site Number : 8400012	San Francisco	California	94143	Recruiting
Investigational Site Number : 8400025	Tampa	Florida	33612	Recruiting
Investigational Site Number : 8400014	Chicago	Illinois	60611	Recruiting
Investigational Site Number : 8400017	Hinsdale	Illinois	60521	Recruiting
Investigational Site Number : 8400010	Ann Arbor	Michigan	48109	Recruiting
Investigational Site Number : 8400019	Edina	Minnesota	55435	Recruiting
Investigational Site Number : 8400018	Las Vegas	Nevada	89107	Recruiting
Investigational Site Number: 8400028	Albuquerque	New Mexico	87109	Recruiting
Investigational Site Number : 8400001	New York	New York	10032	Recruiting
Investigational Site Number : 8400021	Chapel Hill	North Carolina	27599	Recruiting
Investigational Site Number : 8400024	Dallas	Texas	75204	Recruiting
Investigational Site Number : 8400005	El Paso	Texas	79902	Recruiting
Investigational Site Number: 8400016	Houston	Texas	77054	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 54 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06500702, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 4, 2026 · Synced May 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06500702 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →